When we talk about innovation in healthcare, we often think of major breakthroughs or singular discoveries. In reality, in diseases such as amyotrophic lateral sclerosis (ALS), innovation is often quieter. It is the result of many small steps that gradually reshape how we understand the disease and how we can address it.
For years, progress has been slow. Today, however, a shift is beginning to emerge, not because there is an immediate solution, but because the starting point is no longer the same.
A disease that still raises many questions
ALS remains an incurable disease with limited therapeutic options. It is estimated that more than 300,000 people are living with it worldwide, and in most cases there is no clear underlying cause.
This is part of the challenge. Not all patients experience the disease in the same way, nor does it progress uniformly. This variability requires rethinking both how research is conducted and how treatments are developed. A single answer is not enough.
Shifting the focus: understanding what happens inside the cell
One of the most significant advances in recent years has been moving beyond symptoms to focus on what happens at the cellular level.
Proteins such as TDP-43, which is altered in the majority of patients, have taken on a central role in research. This has made it possible to begin developing strategies aimed at intervening directly in the mechanisms that trigger the disease.
This is not a minor shift. It means moving from attempting to slow the consequences to trying to modify the origin.
Researching with models closer to reality
Another factor reshaping the field is how the disease is studied. The use of patient-derived cells in research allows for the creation of in vitro models with greater physiological relevance.
In practice, this helps improve decision-making in early stages. It allows researchers to discard ineffective approaches sooner and focus on those with real potential. In a process that can take years, increasing reliability at these stages is critical.
When research reaches the clinical setting
Every advance must ultimately be validated in patients, and this is where clinical trials come in.
In recent years, Spain has established itself as one of the most active environments for clinical research in Europe. In 2025 alone, the Spanish Agency of Medicines and Medical Devices (AEMPS) authorized 962 clinical trials, a figure that reflects both the system’s capacity and the trust of international companies and institutions.
Beyond the numbers, what matters is the existence of a network of hospitals, professionals, and patients that enables these studies to be conducted rigorously and efficiently. In diseases such as ALS, where time is a critical factor, this makes a real difference.
Technology helping to accelerate progress
Technology is not only accelerating research, it is also transforming how we understand ALS. Today, it is possible to analyze thousands of biological data points simultaneously, observe how cells behave under physiologically relevant conditions, and detect alterations that previously went unnoticed.
For example, advanced cellular models make it possible to observe how certain proteins become mislocalized within neurons or how cellular stress processes are activated. At the same time, biomedical data analysis helps identify patterns that are not immediately apparent, such as relationships between different mechanisms involved in the disease.
All of this does not replace scientific work, but it does make it more precise. It enables better questions, faster validation or rejection of hypotheses, and a more focused effort on pathways that truly have potential impact.
A different moment for ALS research
None of this guarantees immediate results. ALS remains a complex and challenging disease. But it does change the context.
Today, we know more, we have better tools, and we operate in more prepared environments. In a field like this, that is significant.
At Molefy Pharma, this evolving landscape translates into a focus on understanding the mechanisms underlying the disease and advancing that knowledge toward clinical validation. The goal is clear: to ensure that what happens in the laboratory has real translational potential and can, over time, lead to new therapeutic options for patients.